Trading as high as $1.40 earlier this year, LPTN has dropped to the $0.80 level
Lpath made a run at the beginning of this year from the $0.90 level to a high of $1.40. Since then the stock has fallen to lows of around $0.60 with a small rebound back over $0.80 Unlike many of the stock we report on here, LPTH has an excellent cash position of $17M U.S dollars with 1st quarter 2012 revenues topping $2.7M
Did you know? OTCMagic.com is fast becoming THE destination for up to date information on whatever is hot and happening in Penny Stock World. Our STOCK PICKS are Legendary, we alerted LEXG @$1.13 and CBIS @$0.029 and our subscribers saw 1,000% Gains. We rarely announce a STOCK PICK and only email our subscribers once in a long while when we have something truly great so Please Subscribe Right NOW
Lpath is a therapeutic antibody company, a leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2(TM) drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which — iSONEP(TM) for wet AMD and ASONEP(TM) for cancer — have completed Phase 1 clinical trials. Lpath entered into an agreement with Pfizer PFE +0.55% in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.
Lpath, Inc. is the leader in the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lipid-based therapeutics are an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases that currently lack innovative and effective medicines.
Lpath's lead product candidate is iSONEPTM, currently in two clinical trials, including (i) A Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP for the treatment of Pigment Epithelial Detachment (PED) in wet AMD patients; and (ii) A Phase 2 study to determine the safety and efficacy of iSONEP given alone or in combination with Lucentis® or Avastin® in subjects with wet Age-related Macular Degeneration (AMD).
Lpath's second product candidate, ASONEPTM, is a monoclonal antibody against sphingosine-1-phosphate (S1P) that has completed a phase I clinical trial in cancer patients, where it was deemed well tolerated at dose levels up to 24 mg/kg..
Lpath's third product candidate, LpathomabTM is a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been recognized to be involved in diseases of the central nervous system (including pain, traumatic brain injury, neurodegeneration), fibrosis, ocular disease and cancer.
Conclusion: Currently trading at a market valuation of around $60M The Company is developing many new products which may soon come to market. Already doing impressive revenues for a Penny Stock the Company is well funded moving forward. We will see if the stock can move back up over $1 and for a new base in this level.
Latest posts by OTCMAGIC STAFF (see all)
- Did You Know? Monster Stock Pick Coming Tonight - May 3, 2016
- GAWK is The Stock Event Set to Take the BB’s by Storm this week! - December 20, 2015
- Gilead Sciences, Inc. (NASDAQ: GILD) Is a Stock Monster! - September 1, 2015